Veterinary/Animal Vaccines Market to Grow at 5.9% CAGR to 2022 Led by Europe - ReportsnReports

Wednesday, November 8, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

ReportsnReports, November 8, 2017 /PRNewswire/ --

Veterinary/Animal Vaccines Market Size will reach $8.66 billion by

2022 from $6.50 billion in 2017 at a CAGR of 5.9% between (2017-2022) driven by the growth in livestock population and repeated breakouts of livestock diseases; increasing adoption of companion animals; rising incidence
of zoonotic diseases; initiatives by various government agencies, animal associations, and leading players; and the introduction of new types of vaccines in the market.

Browse 148 Market Data Tables and 26 Figures spread through 161 Pages and in-depth TOC on "Veterinary/Animal Vaccines Market by Type (Porcine, Poultry, Companion Animal, Aquaculture), Disease (Porcine Parvovirus, Swine Pneumonia, Avian Influenza, Rabies, Clostridial Diseases), Technology (Inactivated, Toxoid, Recombinant) - Global Forecast to 2022" .

The key players in the veterinary vaccines market are Zoetis (US), Merck Animal Health (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva (France), Phibro Animal Health (US), and Virbac (France). Other notable players operating in this market include Vetoquinol (France), Hester (India), Hipra (Spain), IDT Biologika (Germany), China Animal Husbandry (China), Biogenesis Bago (Argentina), Tianjin Ringpu (China), and Jinyu Bio-technology (China).

Geographically, Europe is the largest market for veterinary vaccines market, followed by North America but the APAC region is expected to witness the highest growth in the forecast period. This growth is primarily attributed to rising pet adoption, expansion of key vaccine players in the region, and the wide range of product launches and investments in veterinary vaccines manufacturing facilities in the region, especially in India, China, and Thailand. Asia Pacific to provide significant growth opportunities during the forecast period.

Make an Inquiry on "Veterinary/Animal Vaccines Market - Global Forecast to 2022" research report at .

The live attenuated vaccines segment is expected to account for the largest share of the veterinary vaccines market in 2017. By technology, the market is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines and other vaccines. In terms of value, the live attenuated vaccines segment is expected to account for the largest share of the market in 2017.The ease of administration and long-term immunity offered by the live attenuated vaccine technologies are driving the demand for this segment in the veterinary vaccines industry.

On the basis of type, the veterinary vaccines market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, companion animal vaccines, aquaculture vaccines, and other vaccines. The companion animal vaccines segment is divided into canine vaccines and feline vaccines and in terms of value, the companion animal vaccines segment is expected grow at the highest CAGR during the forecast period. Increasing awareness about companion animal vaccination, rising prevalence of zoonotic diseases in humans, and the growing number of pets and increasing pet ownership are fueling the demand for these vaccines.

Inquire for Discount on "Veterinary/Animal Vaccines Market - Global Forecast to 2022" research report at .

The veterinary vaccines market in this report is segmented by type, disease, technology, and region. The study tracks and analyzes competitive developments such as product launches; expansions; agreements, partnerships, and collaborations; and acquisitions. It also profiles the key players and their core competencies within the veterinary vaccines market.

Europe expected to dominate the veterinary vaccines market in 2017. Break-up profile of primaries:

  • By Company Type: Tier 1 - 40%, Tier 2 - 35% and Tier 3 - 25%
  • By Designation: C-level - 33%, D-level - 41% and Others - 26%
  • By Region: North America - 35%, Europe - 30%, Asia - 21% and RoW - 14%

Another research titled Vaccine Market Forecast to 2022 says, the vaccines market is expected to reach $49.27 billion by 2022 from $34.30 billion in 2017, at a CAGR of 7.5%. Conjugate vaccines are expected to dominate the market during the forecast period. Monovalent vaccines segment expected to hold the largest share of the market in 2017. Pneumococcal disease segment is expected to witness high growth during the forecast period. Asia to witness high growth during the forecast period. Companies such as GlaxoSmithKline plc, Pfizer, Inc., Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Astellas Pharma Inc., Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, Protein Science Corporation, Panacea Biotec have been profiled in this 204 pages research report available at .

Explore more reports on Biotechnology Market at .

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact: Hrishikesh Patwardhan 2nd Floor, Metropole Building, Next to Inox Theatre, Bund Garden Road, Pune - 411001. Maharashtra, India. +1-888-391-5441

Connect with Us:  LinkedIn: RSS/Feeds:

SOURCE ReportsnReports

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store